Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study - Leal T; Kotecha R; Ramlau R; Zhang L; Milanowski J; Cobo M; Roubec J; Petruzelka L; Havel L; Kalmadi S; Ward J; Andric Z; et al. (The Lancet Oncology, 2023)
FEMU ID: 51618; EMF-Portal URL: https://www.emf-portal.org/en/article/51618